Study for Tirzepatide versus Insulin Glargine

Enroll Now

Type of Study:

An interventional, open label randomized trial of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4)

Title of Study:

Efficacy and Safety of LY3298176 Once Weekly Versus Insulin Glargine in Patients With Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4)

Short Title:

18F-MC-GPGM

Study Length: 108 weeks

Target Age/Sex: over 18 years of age Male and Female

Benefits:

Participants will receive at no cost: study product, study materials and study-specific procedures

Link: ClinicalTrials.gov